https://www.selleckchem.com/pr....oducts/tolebrutinib-
In terms of RI, rheumatologists and RA patients viewed time with optimal QoL R 23.41%/P 35.05%; substantial symptom improvement R 13.15%/P 3.62%; time to onset of treatment action R 16.24%/P 13.56%; severe adverse events R 10.89%/P 11.20%; mild adverse events R 4.16%/P 0.91%; mode of administration R 25.23%/P 25.00%; and added cost R 6.93%/P 10.66%. Nearly 73% of RA patients were involved in treatment decision-making to a greater or lesser extent; however, 27.4% did not participate at all. CONCLUSION Both for rheumatologi
Like
Comment
Share
